Effects of Oxcarbazepine and Levetiracetam on Calcium, Ionized Calcium, and 25-OH Vitamin-D3 Levels in Patients with Epilepsy.
- Author:
Duygu AKSOY
1
;
Betul Tekin GUVELI
;
Pelin Dogan AK
;
Huseyin SARI
;
Dilek ATAKLI
;
Baki ARPACI
Author Information
- Publication Type:Original Article
- Keywords: Antiepileptic drugs; Levetiracetam; Oxcarbazepine; 25-OH vitamin D3; Bone disease
- MeSH: Ambulatory Care Facilities; Anticonvulsants; Bone Diseases; Calcium*; Diagnosis; Epilepsy*; Humans; Prospective Studies
- From:Clinical Psychopharmacology and Neuroscience 2016;14(1):74-78
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: The primary objective of the present study was to further elucidate the effects of oxcarbazepine (OXC) and levetiracetam (LEV) monotherapies on the bone health status of patients with epilepsy. METHODS: This study included 48 patients who attended our epilepsy outpatient clinic, had a diagnosis of epilepsy, and were undergoing either OXC or LEV monotherapy and 42 healthy control subjects. The demographic and clinical features of the patients, including gender, age, onset of disease, daily drug dosage, and duration of disease, were noted. Additionally, the calcium, ionized calcium, and 25-OH vitamin-D3 levels of the participants were prospectively evaluated. RESULTS: The 25-OH vitamin-D3, calcium, and ionized calcium levels of the patients taking OXC were significantly lower than those of the control group. These levels did not significantly differ between the patients taking LEV and the control group, but there was a significant negative relationship between daily drug dose and ionized calcium levels in the LEV patients. CONCLUSION: In the present study, anti-epileptic drugs altered the calcium, ionized calcium, and 25-OH vitamin-D3 levels of epilepsy patients and resulted in bone loss, abnormal mineralization, and fractures. These findings suggest that the calcium, ionized calcium, and 25-OH vitamin-D3 levels of patients with epilepsy should be regularly assessed.
